indiamed
  • News
  • Opinion
  • Interviews
  • IT
  • Finance
  • Strategy
    • Innovation
  • Magazine
  • News
  • Opinion
  • Interviews
  • IT
  • Finance
  • Strategy
    • Innovation
  • Magazine
facebook x icon x icon linkedin linkedin
all-news

Sai Life Sciences sets up Peptide Research Center in Hyd

IMT News Desk

The facility integrates automation, advanced liquid handling, robotics, and high-throughput systems, enhancing precision, scalability, and efficiency in the development of novel peptide-based therapeutics

Innovator-focussed CRDMO Sai Life Sciences inaugurated a dedicated Peptide Research Center at its integrated R&D Campus in Hyderabad. Krishna Kanumuri, CEO and Managing Director, Sai Life Sciences, said, “As the pharmaceutical industry evolves from small molecules to emerging modalities like peptides, we are expanding our capabilities to stay ahead. Our new Peptide Research Center reflects this commitment—designed to meet the growing demand for complex peptide synthesis and conjugation. With this investment, we reinforce our role as a trusted partner in advancing next-generation therapeutics.”

The Peptide Research Center is designed to support innovator pharma and biotech companies with specialised services across peptide synthesis, discovery, and advanced modalities, including complex conjugates. The facility integrates automation, advanced liquid handling, robotics, and high-throughput systems, enhancing precision, scalability, and efficiency in the development of novel peptide-based therapeutics.

Maneesh Pingle, Head of Discovery Services, said: “The demand for peptide-based therapeutics is rising rapidly, driven by their high specificity, biocompatibility, and lower risk of off-target effects. At Sai Life Sciences, we have a seasoned team of scientists with years of experience successfully delivering peptide discovery and development projects. Combined with our expanding capabilities, this expertise positions us strongly to support our clients’ evolving needs as they advance peptide therapies across diverse therapeutic areas."

The new Peptide Research Center will be integrated with Sai Life Sciences’ end-to-end discovery services, spanning synthetic and medicinal chemistry, biology, DMPK, and toxicology. This holistic approach ensures seamless transitions across different stages of drug discovery, accelerating timelines and enhancing success rates for peptide-based drug development.

By combining deep expertise, cutting-edge technology, and an integrated approach, Sai Life Sciences strengthens its commitment to supporting global clients in advancing innovative peptide therapeutics.

Recommended

Karnataka sees steady diabetes burden over a decade: Neuberg Diagnostics

National summit on Diabetic Retinopathy unveils new guidelines with support from Roche India

Glenmark registers consolidated revenue of Rs 60,469 Mn in Q2FY26

Delhi to host 18th edition of CPHI & PMEC India 2025 from Nov 25 to 27, 2025

Pathkind and WebEngage unite to deliver personalised, data-driven patient experiences

Akums reports consolidated revenue of Rs 1,018 crore in Q2 FY26

Apollo Cancer Centre unveils cellular therapy and blood and marrow transplant centre in Bengaluru

Hester Biosciences posts consolidated net profit of Rs 14.33 Cr for Q2 FY25-26

Indiamedtoday

A premier media platform empowering healthcare professionals with critical business insights, news, and innovations to excel in a rapidly evolving industry.

EMAIL editorial@indiamedtoday.com

EMAIL sales@indiamedtoday.com

quick links

news health it interview opinion strategy magazine privacy policy terms and conditions

subscribe to our newsletter

Stay updated with the latest breakthroughs in Indian healthcare, medical research, and wellness insights.

    follow us

    facebook x icon x icon linkedin linkedin
    Copyright © 2025 INDIAMED TODAY Marketed By Screetract Solutions